Recent reviews emphasize that identifying molecular and clinical subtypes of Alzheimer’s disease is critical to advancing precision medicine and improving drug discovery success. Prior to recent modestly effective amyloid-targeting drugs, numerous phase III clinical trial failures underscored the complexity of the disease. Researchers advocate for integrating subtyping strategies to define patient populations better and tailor therapeutic approaches, paralleling successes in oncology. This paradigm shift is poised to transform Alzheimer’s research and treatment development trajectories.